Inhibikase Grants 685,718 Options at $1.68 with Ten-Year Term
Inhibikase Therapeutics granted non-qualified stock options for 685,718 common shares to five new non-executive hires under its 2026 Inducement Equity Plan with an exercise price of $1.68. The options carry a ten-year term, vesting 25% after one year and 75% in 36 equal monthly installments.
1. Inducement Option Awards
Inhibikase Therapeutics’ Board Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) for 685,718 non-qualified stock options to five newly hired non-executive employees, effective March 31, 2026, under the company’s 2026 Inducement Equity Plan.
2. Exercise Price and Term
Each option is exercisable at $1.68, matching the closing common stock price on the grant date, and carries a ten-year term from the effective date.
3. Vesting Schedule
Vesting begins one year after grant with 25% of the options, followed by the remaining 75% vesting in 36 equal monthly installments over the subsequent three years.
4. Dilution Considerations
If fully exercised, the 685,718 options would increase outstanding share count by that amount, potentially weighing on per-share metrics and valuation until expended.